Wealth Enhancement Advisory Services LLC Grows Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.4% in the fourth quarter, Holdings Channel reports. The firm owned 5,980 shares of the medical research company’s stock after buying an additional 197 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Charles River Laboratories International were worth $1,178,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Empirical Finance LLC boosted its stake in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. American Trust lifted its position in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares during the period. OLD National Bancorp IN grew its stake in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares during the last quarter. M&T Bank Corp grew its stake in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 66 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in shares of Charles River Laboratories International by 4.5% in the third quarter. Massmutual Trust Co. FSB ADV now owns 1,842 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 79 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $174.37 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market cap of $8.92 billion, a PE ratio of 21.82, a P/E/G ratio of 4.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $173.81 and a 1 year high of $275.00. The stock has a fifty day moving average price of $193.36 and a 200 day moving average price of $199.12.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the firm earned $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price target for the company. Finally, Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).